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Metabolic diseases, including diabetes (and its complica-
tions), obesity, dyslipidemia, and hypertension, are common
diseases and frequently occur in combination. To study these
diseases,manyhereditaryanimalmodelshavebeenreported,
such as ob/ob mouse, db/db mouse, KK-Ay mouse, Goto-
Kakizaki (GK) rat, Zucker diabetic fatty (ZDF) rat, Otsuka-
Long-Evans-Tokushima-fatty (OLETF) rat, Spontaneously
Diabetic Torii (SDT) rat, spontaneously hypertensive rat
(SHR), Watanabe Heritable hyperlipidemic (WHHL) rabbit,
and Postprandial hypertriglyceridemia (PHT) rabbit. Chem-
ical (e.g., streptozotocin (STZ), alloxan) and diet-induced
(e.g., high sucrose, high fat, high cholesterol) experimental
animal models have been in general use for a long time,
and genetically modified animals have also been used widely
in recent decades. Although molecular biological techniques
have become more important for clarifying the mechanisms
of the diseases, the importance of animal models has not
changed. Animal models are needed to reveal the under-
lying pathophysiology of metabolic diseases; this approach
provides information that is the key to the development of
new therapies and drugs to treat and manage these diseases.
In this special issue, we aim to provide information on
recent beneficial experimental animal models in this field
and present up-to-date information on the pathophysiology,
therapeutic drugs, and diagnosis of metabolic diseases using
v al u a b l ea n i m alm od e l s .W ebe l i ev eth a tth e1 4a rti c l e si nth i s
special issue satisfy these aims.
Type 2 diabetes (T2D) is a complex, multifactorial dis-
ease. Both genetic and environmental factors are known to
contribute to its development; however, the precise patho-
genesis of T2D remains largely unclear. In the present
special issue, various spontaneous T2D rodent models are
summarized in “Spontaneous type 2 diabetic rodent models”
by Y.W. Wang et al.
Several new animal models are introduced in this special
issue. Three papers introduce new diabetic animal models,
SDT rat and its derivative SDT fatty rat. The SDT rat, a
nonobeseT2Dmodel,showsseverehyperglycemiaaccompa-
niedwithhypoinsulinemia.Inthereviewarticle“TheSponta-
neously Diabetic Torii rat: an animal model of nonobese type 2
diabetes with severe diabetic complications” by T. Sasase et al.,
characteristics of diabetic complications in SDT rats, such as
diabeticretinopathy,diabeticperipheralneuropathy,diabetic
neuropathy, and osteoporosis, are described. Among these
diabetic complications, ocular complications are notably a
unique characteristic of this animalmodel. Using this model,
A. Ota et al. evaluated ranirestat, a novel aldose reductase
inhibitorthatiscurrentlyinphaseIIIclinicaltrial,ondiabetic
complications, and report their findings in “Effects of long-
term treatment with ranirestat, a potent aldose reductase2 Journal of Diabetes Research
inhibitor, on diabetic cataract and neuropathy in Sponta-
neously Diabetic Torii rats.” The SDT fatty rat is an obese T2D
model established by introducing the fa allele of Zucker fatty
rat into the SDT rat genome. In the review article “Metabolic
disordersanddiabeticcomplicationsinSpontaneouslyDiabetic
Torii 𝐿𝑒𝑝𝑟
𝑓𝑎 rat: a new obese type 2 diabetic model,” Y.
Kemmochi et al. review the pathophysiological features of
this animal model.
In “A novel rat model of type 2 diabetes: the Zucker
fatty diabetes mellitus ZFDM rat,” N. Yokoi et al. report
the establishment and characteristics of ZFDM rat. This
new T2D model is derived from the ZF rat, presents with
hyperglycemia, and is phenotypically distinct from normo-
glycemic ZF rats. Loss of islet architecture and fibrosis are
also observed in the ZFDM rat. This model is useful for
investigating young- to middle-aged adult-onset T2D.
T. Okamura et al. report the establishment and charac-
teristics of Long-Evans Agouti (LEA) rat derived from Long-
Evans (LE) strain, in “Phenotypic characterization of LEA
rat: a new rat model of nonobese type 2 diabetes.” The LEA
rat displays moderate hyperglycemia and glucose intolerance
along with impaired insulin secretion that is caused by
progressive fibrosis in pancreatic islets. This model is useful
in investigations on the progression of T2D with age.
Three articles describe genetic factors of spontaneous
T2D models, in detail. In “Genetic dissection of complex
genet icf act o ri n vo l vedi nNID D Mo fO LE TFr a t, ”T. Yamada et
al.review1 4QTLs(Nidd1–14/of)identifiedinOLETFratthat
are responsible for noninsulin dependent diabetes mellitus
(NIDDM). Their work showed that NIDDM in the OLETF
rat is a highly heterogeneous and complex genetic disorder.
In “Single diabetic QTL derived from OLETF rat is a sufficient
agent for severe diabetic phenotype in combination with leptin-
signaling deficiency,” H. Kose et al. map hyperglycemia QTLs
intheOLETFratandshowthatNidd2/of ishighlyresponsive
to obesity. In addition, Nidd2/of and another hyperglycemia
QTL, Nidd1/of, appear to act in combination to lead to the
developmentofdiabetes.Theirnewcongenicstrain,carrying
asingleQTL,maybehelpfulinidentifyingthecausativegene
and should aid future investigations on understanding the
mechanism by which obesity interacts with QTLs to regulate
diabetic traits.
In the article “Dose effect and mode of inheritance of
diabetogenic gene on mouse chromosome 11,” N. Babaya et
al. revealed that the introgression of chromosome 11 of
T2D Nagoya-Shibata-Yasuda (NSY) strain onto nondiabetic
C3H caused marked changes in glucose tolerance and STZ
susceptibility, even in heterozygous state. However, hyper-
glycemia and STZ sensitivity in heterozygous C3H-11
NSY
mouse was not as severe as in the homozygous mouse. The
consomic strains constructed in their studies will facilitate
finemappingandidentificationofresponsiblegenesforT2D-
related phenotypes.
Islet transplantation is an effective treatment for severe
diabetes. N. Sakata et al. review three types of animal
models (STZ-induced diabetes, pancreatomized diabetes,
and spontaneous diabetes) used for preclinical islet trans-
plantation research in “Animal models of diabetes mellitus for
islet transplantation.” As highlighted in this review, selecting
t h ea p p r o p r i a t em o d e l sb a s e do nt h es t u d y ’ so b j e c t i v ei s
paramounttoproperlyinterpretastudy’sfindingsandcritical
to advance this area of research.
Cardiovascular disorders (CVDs) are the leading cause
of death in humans. In “Cardiovascular changes in animal
models of metabolic syndrome” by A. M. Lehnen et al.,
c a r d i o v a s c u l a rfi n d i n g si na n i m a lm o d e l sw i t ho b e s i t y ,d y s -
lipidemia,diabetes,orhypertensionaresummarized.Theuse
of different experimental models is important in order to
better understand the mechanisms involved in CVDs caused
by metabolic disease.
Because the mortality due to CVD is greater in type 1
diabetic (T1D) patients than in the general population, C. H.
Hung et al. aimed to investigate the severity of cardiopul-
monary dysfunction caused by lipopolysaccharide (LPS)
in T1D rats in “Cardiopulmonary profile in streptozotocin-
induced type 1 diabetic rats during systemic endotoxemia.” In
this study, despite higher TNF-𝗼 l e v e li ns e r u ma n db r o n -
choalveolar lavage fluid between nondiabetic and STZ T1D
rats, there was only a modest difference of cardiopulmonary
dysfunction between the two groups.
T1D is an autoimmune disease that is characterized by
the selective destruction of pancreatic 𝗽 cells. Both envi-
ronmental and genetic factors are known to contribute to
the progression of this autoimmunity. In the review article
“Rodent models for investigating the dysregulation of immune
responses in type 1 diabetes” by F. C. Chou et al., non-
obesediabetic(NOD)mouseandotherspontaneousdiabetes
models are introduced. In addition, this review discusses
genetically manipulated NOD mice that overexpress protec-
tive genes in islet, T-cell receptors, islet-specific neoantigens,
or humanized MHC.
Lastly, in their review article entitled “𝐹𝑜𝑥𝑝3
+ regulatory
T cells in mouse models of type 1 diabetes,” C. Petzold et al.





In this review, spontaneous and genetically engineered NOD
mice for studying the role of Foxp3
+ Treg cells in 𝗽 cell
autoimmunity are overviewed.
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